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Abstract
Survival rates for patients with pancreatic cancer are extremely poor due to its asymptomatic progression to advanced and
metastatic stage for which current therapies remain largely ineffective. Therefore, novel therapeutic agents and treatment
approaches are desired to improve the clinical outcome. In this study, we determined the effects of honokiol, a biologically
active constituent of oriental medicinal herb Magnolia officinalis/grandiflora, on two pancreatic cancer cell lines, MiaPaCa
and Panc1, alone and in combination with the standard chemotherapeutic drug, gemcitabine. Honokiol exerted growth
inhibitory effects on both the pancreatic cancer cell lines by causing cell cycle arrest at G1 phase and induction of apoptosis.
At the molecular level, honokiol markedly decreased the expression of cyclins (D1 and E) and cyclin-dependent kinases
(Cdk2 and Cdk4), and caused an increase in Cdk inhibitors, p21 and p27. Furthermore, honokiol treatment led to
augmentation of Bax/Bcl-2 and Bax/Bcl-xL ratios to favor apoptosis in pancreatic cancer cells. These changes were
accompanied by enhanced cytoplasmic accumulation of NF-kB with a concomitant decrease in nuclear fraction and
reduced transcriptional activity of NF-kB responsive promoter. This was associated with decreased phosphorylation of
inhibitor of kappa B alpha (IkB-a) causing its stabilization and thus increased cellular levels. Importantly, honokiol also
potentiated the cytotoxic effects of gemcitabine, in part, by restricting the gemcitabine-induced nuclear accumulation of
NF-kB in the treated pancreatic cancer cell lines. Altogether, these findings demonstrate, for the first time, the growth
inhibitory effects of honokiol in pancreatic cancer and indicate its potential usefulness as a novel natural agent in
prevention and therapy.
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Introduction
Pancreatic cancer is one of the most lethal malignancies in the
United States with mortality rate increasing every coming year [1,2].
According to the estimate of American Cancer Society, 43140
Americans were diagnosed with pancreatic cancer in 2010 and
36,800 died, marking this malignancy as the fourth leading cause of
death from cancer [2]. Due to its asymptomatic progression,
pancreatic cancer is diagnosed at a stage when it has already
metastasized or is locally advanced [3]. Therapeutic approaches
against the advanced disease have largely failed and approximately
.80% of patients diagnosed with this malignancy still die within 2–8
months [4]. Gemcitabine, a standard FDA approved drug for
pancreatic cancer therapy, is reported to be minimally effective that
improves patient’s survival by couple of weeks only [3,5]. Therefore,
it is of utmost importance to develop alternative therapeutic regimens
and strategies for effective management of pancreatic cancer.
Several new strategies, which target growth promoting path-
ways alone and in combination with gemcitabine, have been tested
in pancreatic cancer to improve therapeutic outcome [6]. In
addition, several recent studies have identified deregulated
signaling elements, such as Ras, Akt, NF-kB, miRNAs, etc., that
not only promote cancer progression but also confer chemoresis-
tance in pancreatic cancer [7–9]. Induction of these survival
pathways results from activating gene mutations, loss of inhibitory
pathways and/or potentiation through autocrine and paracrine
signaling mechanisms [3,10]. In fact, it has now been shown that
targeting of some of these signaling nodes can be useful in
inhibiting tumor growth and progression as well as in restoring the
sensitivity of tumor cells to the cytotoxic drugs [3,9,10].
Natural products have been at the core of cancer chemotherapy
for past several decades and in fact, over 60% of the current
anticancer drugs have their origin from natural sources [11]. In
several recent studies, novel plant-derived compounds have been
identified to act as anti-tumor agents through modulation of
biological pathways [12]. Honokiol, a biologically active biphe-
nolic compound isolated from the Magnolia officinalis/grandiflora, has
received significant attention due to its potent anti-neoplastic and
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21573anti-angiogenic properties [13,14]. It has yielded promising data
against skin, colon, lung and breast cancers [13,15–17]. The
striking aspect of honokiol as an anti-neoplastic drug is its potential
to inhibit nuclear factor kappa B (NF-kB), which is associated with
cancer cell survival and chemoresistance [9,10,18]. The NF-kBi s
constitutively activated in a variety of hematologic and solid
malignancies, including pancreatic cancer and controls the
expression of an array of genes involved in cell proliferation and
survival through direct and indirect mechanisms [18–20]. In the
present study, we have examined, for the first time, the effects of
honokiol against pancreatic cancer. Our data show that honokiol
inhibits the growth of human pancreatic cancer cell lines,
MiaPaCa and Panc1, by causing cell cycle arrest and induction
of apoptosis. Furthermore, our study provides evidence for a role
of honokiol in chemosensitizing the pancreatic cancer cells to
cytotoxic effects of gemcitabine.
Results
Growth inhibitory effect of honokiol on human
pancreatic cancer cells
Two human pancreatic cancer cell lines viz. MiaPaCa and
Panc1 were employed as a model system to investigate the effect of
honokiol on pancreatic cancer cell growth. Cells treated with
honokiol (10–60 mM) showed alterations in morphology as
compared to vehicle (DMSO)-treated cells. With increasing
concentration of honokiol, cells became round, shrunken and
detached from the substratum (Figure 1A), consistent with
morphological changes associated with apoptosis. Subsequently,
we quantified the cytotoxic effects of honokiol by measuring
percent viability using WST-1 assay. Our data demonstrated that
honokiol induced a dose- and time- dependent decrease in growth
of both the pancreatic cancer cell lines with IC50 values of ,43.25,
31.08 and 18.54 mM (against MiaPaCa), and ,47.44, 34.17 and
21.86 mM (against Panc1) after 24, 48 and 72 h treatments,
respectively (Figure 1B). Together, these findings indicate that
honokiol has growth inhibitory effects on pancreatic cancer cells.
Honokiol causes G1 phase cell cycle arrest and induces
apoptosis in pancreatic cancer cells
Suppression of cancer cell growth can be caused either by arrest
of cell cycle progression or due to induction of apoptosis or both
[12]. Our data on cell cycle distribution demonstrated that
treatment with honokiol resulted in enrichment of pancreatic
cancer cells in G1 phase with a concomitant decrease in number of
cells in S-phase (proliferative fraction) (Figure 2). We observed a
,1.28, 2.16 and 2.46 folds (in MiaPaCa) and ,1.08, 1.53 and
1.93 folds (in Panc1) decrease in number of cells in S-phase at 20,
40 and 60 mM doses of honokiol, respectively (Figure 2). In
apoptosis assays, our data demonstrated a considerable increase in
apoptotic index (PE Annexin V positive/7AAD negative cells) in a
dose-dependent manner after 24 h of honokiol treatment
(Figure 3). At 20, 40 and 60 mM concentrations of honokiol, we
observed ,1.25, 2.04 and 3.96 folds increase in apoptotic indices
of MiaPaCa and ,1.34, 1.98 and 3.32 folds increase in apoptotic
indices of Panc1 cells, respectively. Altogether, our findings
demonstrate that honokiol has both cytostatic and cytotoxic
properties against pancreatic cancer cells.
Honokiol alters the expression of cell-cycle and survival-
associated proteins
To investigate the mechanistic basis of growth inhibitory effects
of honokiol, we next examined its effect on the expression of key
proteins involved in cell proliferation and survival. Our data
revealed a dose-dependent decrease in the expression of cyclins
(D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4); while
an induced expression of cyclin-dependent kinase inhibitors (p21
and p27) was observed after honokiol treatment in both MiaPaCa
and Panc1 pancreatic cancer cells (Figure 4). Among the survival
proteins, we observed a dose-dependent reduction in the levels of
the anti-apoptotic protein Bcl-2 and Bcl-xL, whereas a concom-
itant increase in the level of pro-apoptotic protein Bax was
observed (Figure 5A) leading to an increase in the ratio of Bax/
Bcl-2 (Figure 5B, upper panel) and Bax/Bcl-xL (Figure 5B, lower
panel). These findings demonstrate that honokiol alters the
expression of proteins involved in the regulation of cell cycle and
apoptosis to confer its growth inhibitory effect.
Honokiol attenuates the constitutive activation of NF-kB
in human pancreatic cancer cells
NF-kB is constitutively active in many cancer types, including
pancreatic cancer [18–20] and it has been shown that the
activation of this signaling node facilitates cell cycle progression
[21] and apoptotic resistance [22]. Therefore, we investigated
whether the treatment of pancreatic cancer cells with honokiol has
an impact on NF-kB activation in pancreatic cancer cells. We first
examined the effect of honokiol on the transcriptional activity of
NF-kB- responsive promoter in a luciferase reporter assay. Our
data indicated a dose-dependent reduction in transcriptional
activity of NF-kB( ,1.40, 2.08 and 4.0 folds in MiaPaCa, and
,1.29, 1.96 and 5.26 folds in Panc1 cells) at 20, 40 and 60 mMo f
honokiol treatment, respectively (Figure 6A). To further support
this observation, we next studied the cellular localization
(cytoplasmic vs. nuclear) p65 subunit of NF-kB. Our immunoblot
data demonstrated that honokiol treatment caused a marked and
dose-dependent decrease in NF-kB levels in the nuclear fraction of
both MiaPaCa and Panc1 pancreatic cancer cells with a
simultaneous increase in the cytoplasmic fraction (Figure 6B).
Cellular distribution of NF-kB is controlled by relative expression
of its biological inhibitor IkB, which keeps NF-kB sequestered in
cytoplasm in an inactive complex [23]. Therefore, we analyzed the
cytoplasmic extracts of honokiol-treated pancreatic cancer cells for
determination of IkB-a level. Our data demonstrated a dose-
dependent increase in the level of the IkB-a upon honokiol-
treatment (Figure 6B). This was associated with a concomitant
decrease in IkB-a phosphorylation indicating increased stabiliza-
tion of IkB-a after exposure to honokiol. Altogether, our data
indicate that honokiol suppresses constitutive activation of NF-kB
in pancreatic cancer cells.
Honokiol chemosensitizes the pancreatic cancer cells for
gemcitabine toxicity
Gemcitabine is the only FDA-approved chemotherapeutic drug
against pancreatic cancer; however, it remains minimally effective
due to chemoresistance [3,5,10]. Since activation of NF-kBi s
considered as one of the mechanisms potentiating chemoresis-
tance, we examined if honokiol would act as a chemosensitizer in
pancreatic cancer cells. Pancreatic cancer cells (MiaPaCa and
Panc1) were treated with gemcitabine alone or in combination
with to sub-IC50 concentrations of honokiol and effect on growth
inhibition was examined using cell viability assay. Our data
demonstrated that gemcitabine inhibited the growth of pancreatic
cancer cells in a dose-dependent manner and combined treatment
with honokiol led to a significant reduction in the IC50 of
gemcitabine (Figure 7A). At 10 and 20 mM doses of honokiol,
respectively, a ,1.53 and 2.41 fold (in MiaPaCa) and ,1.40 and
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signifying the chemosensitizing effect of honokiol (Figure 7A). To
identify a role of NF-kB, we examined its cellular localization in
gemcitabine (alone or in combination with honokiol)-treated
pancreatic cancer cells. Our data displayed an enhanced
accumulation of NF-kB in nuclear compartment and a concom-
itant decrease in cytoplasmic fraction with increasing doses of
gemcitabine in both MiaPaCa and Panc1 cells (Figure 7B).
Notably, we observed that honokiol (even at 20 mM dose) was
effective in inhibiting the gemcitabine-induced activation of NF-
kB in both MiaPaCa and Panc1 cells (Figure 7C). These findings
clearly suggest that honokiol potentiates the anti-tumor efficacy of
gemcitabine by acting as a chemo-sensitizer in pancreatic cancer
cells.
Discussion
Pancreatic cancer remains a devastating malignancy due to lack
of effective therapy for treatment [3]. The present study
demonstrated that honokiol (a natural biphenolic compound) is
effective in suppressing the growth of human pancreatic cancer
cells (MiaPaCa and Panc1) due to its cytostatic and cytotoxic
properties. Furthermore, our studies provided evidence for a role
of honokiol in chemosensitizing the pancreatic cancer cells to
gemcitabine toxicity. Honokiol inhibited NF-kB activity and
caused altered expression of many cell cycle and survival-
associated proteins to confer its growth suppressive and chemo-
sensitizing effects in pancreatic cancer cells.
Deregulated growth in cancer cells is often attributed to loss of
control in proliferative and apoptotic pathways [24]. In fact,
molecular studies have revealed that the expression of cell cycle
regulators and proteins associated with cell survival is frequently
altered in multiple human cancers [25–27]. Cell cycle is regulated
by concerted actions of cyclins, cyclin-dependent kinases (Cdks)
and Cdks inhibitors [26,28]. We observed that the treatment of
pancreatic cancer cells with honokiol resulted in G1-phase arrest of
cell cycle progression, along with reduction in cyclin D1, cyclin E,
Cdk2 and Cdk4 and increase in p21 and p27 at the protein level.
Cyclin D1 and its catalytic partner Cdk4 dominate in G1 phase,
whereas, cyclin E and Cdk2 complex regulates the cell-cycle
progression from G1 to S [26,28]. Therefore, our findings indicate
that the honokiol-induced arrest of pancreatic cancer cells in G1
cell cycle phase might be mediated through the downregulation of
cyclins and Cdks along with the upregulation of p21 and p27
Figure 1. Honokiol suppresses growth of human pancreatic cancer cells. (A) MiaPaCa and Panc1 cells were seeded in 6 well plate
(1610
5 cells/well) and allowed to attain 70–80% confluence prior to honokiol (10–60 mM) treatment for 48 h. Following treatment, significant change
in cell morphology was observed of both the cell types as examined under phase-contrast microscope. Cells became round, shrunken and detached
from cell surface in a dose-dependent manner. Representative micrographs are from one of the random fields of view (magnification 200X) of cells
treated with 20, 40 or 60 mM honokiol. (B) MiaPaCa and Panc1 cells were grown in 96 well microtitre plates (1610
4 cells /well) and treated with
honokiol (10–60 mM) at 70–80% confluence. Percent viability of cells was measured by WST-1 assay after 24, 48 and 72 h. An OD value of control cells
(treated with an equal volume of DMSO, final concentration, ,0.1%) was taken as 100% viability. Honokiol inhibited cell viability in a dose- and time-
dependent manner for both the cell types suggesting anti-tumor effect of honokiol. Data are expressed as mean6 SD; (n=3).
doi:10.1371/journal.pone.0021573.g001
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and cyclins to inhibit their activity [29]. These results are in
accordance with earlier studies on the effect of honokiol in human
lymphoid leukemia, squamous lung cancer and breast cancer cells
[16,17,30].
Following G1-phase cell cycle arrest, cells may either undergo
repair or enter the apoptotic pathway to maintain cellular integrity
and elimination of erred/mutated pre-malignant and neoplastic
cells [31]. Thus, the induction of apoptosis is one of the protective
mechanisms against cancer initiation and progression and cancer
cells have often acquired resistance to apoptosis [24]. In the
present study, we observed significant induction of apoptosis in
honokiol-treated pancreatic cancer cells indicating that honokiol is
able to potentiate the apoptotic machinery. Cell survival is
maintained by a fine balance of the ratios of pro-apoptotic (e.g.,
Bad and Bax) and anti-apoptotic proteins (e.g., Bcl-2 and Bcl-xL),
which control the process of apoptosis through release of caspases
[32,33]. Therefore, altered expression of the Bcl-2 family proteins
observed upon honokiol treatment of pancreatic cancer cells in a
manner that favors the increase in the ratios of Bax/Bcl-2 and
Bax/Bcl-xL could underlie the observed apoptotic effect of
honokiol. Deregulation of apoptosis-related proteins has also been
reported in chondrosarcoma cells after honokiol treatment further
supporting its role in apoptosis induction [34].
We also observed inhibition of NF-kB activity upon honokiol
treatment, which was associated with inhibition of IkB-a
phosphorylation and concomitant increase in its expression.
Transcription factor NF-kB is constitutively activated in multiple
malignancies and has been reported to be pathologically
implicated in pancreatic cancer [18–20]. Recent studies have
shown that the growth-suppressive effect of honokiol in prostate
and colon cancers is mediated through the inhibition of NF-kB
[35]. The NF-kB transcription factor is composed of heterodimers
consisting of Rel (p65, c-Rel and RelB), p52, and p50 proteins and
is localized in the cytoplasm in its inactive form in complex with
IkB (inhibitor of NFkB consisting of a and b subunits that masks
its nuclear localization signal [36]. Activation of NF-kB is caused,
when IkB-a gets phosphorylated by the IKK (inhibitor kinase)
complex leading to its ubiquitination and degradation. This results
in the release of NFkB from the cytoplasm and transport into the
nucleus followed by activation of NF-kB-responsive promoter. NF-
kB is known to induce the expression of cyclin D1, Bcl-2 and Bcl-
xL (altered upon honokiol treatment in current study) along with
an array of proteins involved in cell proliferation and survival
Figure 2. Honokiol causes G1 phase cell cycle arrest in human pancreatic cancer cells. MiaPaCa and Panc1cells (1610
6 cells/well) were
synchronized by culturing in serum free media for 72 h, followed by incubation in serum-containing media for 24 h and subsequent treatment with
either honokiol (20, 40 or 60 mM) or DMSO (control) for 24 h. Distribution of cells in different phases of cell cycle was analyzed by propidium iodide
(PI) staining followed by flow cytometry. Enhanced accumulation of MiaPaCa and Panc1 cells in the G1 phase of the cell cycle was observed after
treatment with honokiol in a dose-dependent manner (as indicated by flow histograms) with a concomitant decrease in S-phase cells.
doi:10.1371/journal.pone.0021573.g002
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pancreatic cancer cells by honokiol is mediated through the
inhibition of NF-kB.
Clinical outcome in pancreatic cancer has remained poor due to
advanced and metastatic state of the disease at the time of
diagnosis and ineffectiveness of allowable drug-therapy due to
chemoresistance [3,5,10]. Currently, gemcitabine is the national
standard chemotherapeutic drug for pancreatic cancer treatment.
Gemcitabine interferes with DNA synthesis leading to cell cycle
arrest and apoptosis in ultimate course [39,40]. One of the
mechanisms that limits gemcitabine efficacy is induced activation
of NF-kB in response to its treatment [41], which may cause
apoptotic delay or suppression. In this study, we have shown
chemosensitizing effect of honokiol on pancreatic cancer cells to
gemcitabine toxicity. Additionally, we showed that gemcitabine
treatment induced nuclear accumulation of NF-kB, which could
be effectively inhibited by co-treatment with honokiol. These
parallel findings indicate that the inhibition of NF-kB activity may
also mediate the chemosensitization of pancreatic cancer cells by
honokiol. Indeed, it has been reported earlier that anti-cancer
effects of chemotherapeutic agents can be potentiated by
inhibition of NF-kB activity [22,41].
In conclusion, we have shown, for the first time, the growth
inhibitory and chemosensitizing potential of honokiol in pancre-
atic cancer. Honokiol causes G1 phase cell cycle arrest and
induction of apoptosis by altering the expression of cell cycle and
survival associated proteins. Inhibition of NF-kB may be one of
the significant mechanisms in honokiol-induced growth suppres-
sive and chemosensitizing effects in pancreatic cancer cells. We
therefore believe that honokiol could be a novel promising natural
agent for the treatment of pancreatic cancer and may also serve as
a chemosensitizer to improve the therapeutic efficacy of
gemcitabine, which is already in clinical use as a therapeutic drug.
Materials and Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) and Roswell
park memorial institute (RPMI-1640) medium were obtained from
Thermo Scientific (Logan, UT). Fetal-bovine serum (FBS) was
from Atlanta Biologicals (Lawrenceville, GA). Penicillin, strepto-
mycin and trypsin-EDTA were purchased from Invitrogen
(Carlsbad, CA). Honokiol was procured from LKT Laboratories
(St. Paul, MN). Gemcitabine was provided by USAMCI
pharmacy. FuGENE transfection reagent, phosphatase/protease
inhibitors cocktail and cell proliferation reagent WST-1 were
procured from Roche Diagnostics (Mannheim, Germany). Propi-
dium iodide/RNAse staining buffer and PE Annexin V apoptosis
detection kit were purchased from BD Bioscience (San Diego,
CA). Nuclear extract kit was procured from Active Motif, LLC
Figure 3. Honokiol induces apoptosis in human pancreatic cancer cells. MiaPaCa and Panc1 cells were grown in 6-well plates (1610
6 cells /
well) and allowed to attain 70–80% confluence. Cells were treated with either honokiol (20, 40 or 60 mM) or DMSO (control) for 24 h and
subsequently stained with 7-AAD and PE Annexin V followed by flow cytometry. The lower left quadrants of each panels show the viable cells
(negative for both, PE Annexin V and 7-AAD). The upper right quadrants contain necrotic or late apoptotic cells (positive for both, PE Annexin V and
7-AAD). The lower right quadrants represent the early apoptotic cells (PE Annexin V positive and 7-AAD negative). Data show a dose-dependent
increase in the number of apoptotic cells in both MiaPaCa and Panc1 cells after treatment with honokiol as compared to control cells, indicating
apoptotis inducing potential of honokiol.
doi:10.1371/journal.pone.0021573.g003
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cancer cells (MiaPaCa and Panc1) were treated with either honokiol (20, 40 or 60 mM) or DMSO (control) for 24 h. Total protein was isolated and
subjected to immunoblot analysis for various cell cycle-associated proteins (cyclin D1, cyclin E, Cdk2, Cdk4, p21 and p27). b-actin was used as a
loading control. Intensities of the immunoreactive bands were quantified by densitometry. Normalized densitometric values are indicated at the top
of the bands exhibiting a dose-dependent decrease in the expression of cyclin D1, cyclin E, Cdk2 and Cdk4 and increase in the expression of cyclin
inhibitors; p21 and p27, after exposure to honokiol, in both the cell types.
doi:10.1371/journal.pone.0021573.g004
Figure 5. Honokiol modulates Bax/Bcl-2 and Bax/Bcl-xL ratio in human pancreatic cancer cells. (A) MiaPaCa and Panc1 cells were treated
with either honokiol (20, 40 or 60 mM) or DMSO (control) for 24 h. Immunoblotting was performed for Bcl-xl, Bcl-2 and Bax proteins followed by
densitometry of immunoreactive bands. Normalized densitometric values are indicated at the top of the bands. (B) Bar diagram summarizing the
effects of honokiol treatment on Bax/Bcl-2 ratio (upper panel) and Bax/Bcl-xL ratio (lower panel). Data suggest that honokiol induces apoptosis by
upregulating pro-apoptotic Bax and downregulating anti-apoptotic Bcl-2 and Bcl-xL proteins.
doi:10.1371/journal.pone.0021573.g005
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(Ser32/36) (rabbit polyclonal), Bcl-xl and NF-kB/p65 (rabbit
monoclonal), and IkB-a (mouse monoclonal) were obtained from
Cell Signaling Technology (Beverly, MA). Antibodies against p21,
Cdk4 (mouse monoclonal), p27, cyclin D1, cyclin E, Cdk2 (rabbit
polyclonal), and horseradish peroxidase-conjugated secondary
antibodies were procured from Santa Cruz Biotechnology (Santa
Cruz, CA). b-Actin (mouse monoclonal) antibody was purchased
from Sigma-Aldrich (St. Louis, MO). ECL plus western blotting
detection kit was procured from Thermo Scientific.
Figure 6. Honokiol attenuates constitutive NF-kB activation by inhibiting nuclear translocation of NF-kB/p65 in human pancreatic
cancer cells. (A) MiaPaCa and Panc1cells (0.5610
6 cells/well) were seeded in 12-well plate. Next day at 60% confluence, cells were co-transfected
with NF-kB luciferase reporter and TK-Renilla luciferase (control) plasmids. Twenty-four hours post-transfection, cells were treated with honokiol (20,
40, or 60 mM) for next 24 h. Protein lysates were made and luciferase (Fire-fly; test and Renilla, transfection efficiency control) activity assessed using a
dual-luciferase assay system. Data is presented as normalized fold-change in luciferase activity (mean6 SD; n=3, * p,0.05). (B) Total, nuclear and
cytoplasmic extracts were prepared from cells treated with honokiol (20, 40, or 60 mM) for 6 h and expression of NF-kB/p65, p-IkB-a (S32/36) and IkB-
a was determined by Western blot analysis. b-actin was used as a loading control. Intensities of the immunoreactive bands were quantified by
densitometry. Normalized densitometry values are indicated at the top of the bands indicating a decreased localization of NF-kB/p65 in nucleus with
a concomitant increase in cytoplasm. In contrast, expression of p-IkB-a was decreased leading to increased levels of IkB-a. Altogether, these data
clearly suggest that honokiol inhibits NF-kB activity through stabilization of IkB-a.
doi:10.1371/journal.pone.0021573.g006
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and Dual Luciferase Assay System kit were from Promega
(Madison, WI).
Cell culture and treatments
The human pancreatic cell lines MiaPaCa and Panc1 (ATCC,
Manassas, VA) were maintained in culture as adherent monolayer
in RPMI-1640 and DMEM respectively, supplemented with 10%
(v/v) FBS, penicillin (100 units/mL) and streptomycin (100 mg/
mL). Cells were maintained in 5% CO2 humidified incubator at
37uC. Growth medium was changed every 3 day and cells were
split (1:3) when they reached 80% confluence. For treatments,
stock solution of honokiol (10 mmol/L) was prepared in DMSO,
stored at 220uC, and diluted with fresh complete medium
immediately before use. Cells were treated with various concen-
trations of honokiol alone, gemcitabine alone or in combination (as
specified in the figure legends). An equal volume of DMSO (final
concentration, ,0.1%) was added to the control.
Cell growth assay
Cells were seeded in 96 well plates (1610
4 cells/well) a day
prior to treatments. Cell viability in the treated cells was examined
after 24–72 h by using WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophe-
nyl)-2H-5-tetrazolio]-1, 3-benzene di-sulfonate) assay kit as per
manufacturer’s instructions with appropriate controls. This assay is
based on the cleavage of WST-1 in metabolically active cells to
form water-soluble formazan. The absorbance of the formazan
was measured at a wavelength of 450 nm, with background
subtraction at 630, using a Bio-Rad Benchmark microplate reader
(Bio-Rad Laboratories, Hercules, CA). Growth was calculated as
percent viability = [(A/B)6100], where A and B are the
absorbance of treated and control cells, respectively.
Cell-cycle analysis
The effect of honokiol treatment on cell cycle progression was
determined by flow cytometry following staining with propidium
iodide (PI). In brief, cells (1610
6 cells/well) were seeded in 6 well
plate and synchronized by culturing them in serum free media.
After 48 h, medium was replaced with complete medium
containing desired concentrations of honokiol or DMSO. Floating
and attached cells were collected after 24 h of treatment and fixed
in 70% ethanol overnight at 4uC. The cells were then stained with
propidium iodide, using PI/RNase staining buffer for 1 h at 37uC.
Stained cells were analyzed by flow-cytometry on a BD-FACS
Figure 7. Honokiol chemo-sensitizes pancreatic cancer cells to gemcitabine treatment. (A) MiaPaCa and Panc1 cells were grown in 96 well
microtitre plates (1610
4 cells/well). At sub-confluence, cells were treated with gemcitabine (1.25–40 mM) alone or in combination with honokiol (10
or 20 mM) for 48 h. Percent viability was measured by WST-1 assay. Data are presented as relative percent viability with respect to untreated or
honokiol only-treated cells to control for the growth suppressive effects of honokiol (mean6 SD; n=3. *, p,0.05). A significant decrease in IC50 values
of gemcitabine was observed in cells co-treated with honokiol. (B) Cells were treated with gemcitabine (5, 10 and 20 mM) for 6 h and expression of
NF-kB/p65 in nuclear, cytoplasmic and total cell lysates was determined by Western blot analysis. Gemcitabine treatment of cells resulted in
enhanced nuclear accumulation of NF-kB/p65 in a dose dependent manner (C) Nuclear and cytoplasmic extracts were prepared from cells treated
with gemcitabine (10 mM), honokiol (20 mM) alone or in combination for 6 h. Expression of NF-kB/p65 in nuclear, cytoplasmic and total cell lysates
was determined by Western blot analysis. Data shows that honokiol co-treatment restricted gemcitabine-induced NF-kB/p65 nuclear accumulation.
Together, these findings suggest that honokiol acts as a chemosensitizer and increases the cytotoxic effects of gemcitabine in pancreatic cancer.
doi:10.1371/journal.pone.0021573.g007
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TM II (Becton-Dickinson, San Jose, CA) to calculate the
percentage of cell population in various phases of cell cycle using
Mod Fit LT software (Verity Software House, Topsham, ME).
Apoptosis analysis
MiaPaCa and Panc1 cells were seeded (1610
6 cells/well) in 6
well plate. After overnight incubation, cells were treated with
either control vehicle (DMSO) or various concentrations of
honokiol for 24 h. Following treatment, cells were harvested,
and stained with 7-Amino-Actinomycin (7-AAD) and PE Annexin
V, using PE Annexin V Apoptosis Detection Kit I, followed by
flow cytometry. Percentage of cell population in apoptosis was
calculated using Mod Fit LT software.
Nuclear and cytoplasmic fractionation
The preparation of cytoplasmic and nuclear extracts was
performed using the Nuclear Extract Kit. In brief, cells were
washed following treatment with 1 mL ice-cold PBS/phosphatase
inhibitors, lysed in 500 mL hypotonic buffer and then centrifuged
at 14,000 g for 30 s at 4uC. After collecting supernatant
(cytoplasmic fraction), pellets were resuspended in 50 mL complete
lysis buffer, and centrifuged at 14,000 g for 10 min at 4uC, and
supernatant (nuclear fraction) were stored at 280uC.
Western blot analysis
Cells were processed for protein extraction and western blotting
as described earlier [10]. Immunodetection was carried out using
specific antibodies: Bcl-2, Bcl-xL, Bax, NF-kB/p65, p-IkB-a
(Ser32/36), IkB-a (1:1000), Cdk2, Cdk4, Cyclin D1, Cyclin E,
p21, p27 (1:200) and b-actin (1:20000). All respective secondary
antibodies were used at 1:2500 dilutions. Blots were processed with
ECL plus Western Blotting detection kit and the signal detected
using an LAS-3000 image analyzer (Fuji Photo Film Co., Tokyo,
Japan). Densitometry was performed using an AlphaImager
(Alpha Innotech Corp., San Leandro, CA).
NF-kB transcriptional activity assay
To measure the NF-kB transcriptional activity, pancreatic
cancer cells were seeded (0.5610
6 cells/well) in 12-well plate.
After 60% confluence level, the cells were transiently transfected
with 1 mg of NF-kB -luciferase promoter-reporter construct
(pGL4.32 [luc2P/NF-kB -RE/Hygro]) and 0.5 mg of control
reporter plasmid (pRL-TK), containing Renilla reniformis lucif-
erase gene downstream of the TK promoter. Transfections were
carried out using FuGENE as a transfection reagent according to
the manufacturers’ recommendations. Twenty-four hours after
transfection, the cells were treated with honokiol for next 24 h,
washed with ice cold PBS, and harvested in reporter lysis buffer.
Luciferase activity was measured using the Dual Luciferase Assay
System. All experiments were carried out in triplicate and relative
luciferase activity reported as the fold induction after normaliza-
tion for transfection efficiency.
Statistical analysis
All the experiments were performed at least three times,
independently. A logistic regression model was fit to the data using
R statistical software to calculate the IC50. The data obtained were
expressed as ‘mean 6 standard deviation’. Wherever appropriate,
the data were also subjected to unpaired two tailed Student’s t-test.
A value of p,0.05 was considered as significant.
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